Nordisk Pharma ApS: Financial statements 2023
CVR: 42852287
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Nordisk Pharma ApS (CVR 42852287) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 331,910 and a net result of DKK 262,984. Equity in the 2023 report amounted to DKK 583,982. The solvency ratio was 78.2%.
- Gross Profit
- DKK 331,910
- Profit/Loss
- DKK 262,984
- Equity
- DKK 583,982
- Total Assets
- DKK 746,600
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Nordisk Pharma ApS has published its interim report for the period November 17, 2021 – December 31, 2022.
About Nordisk Pharma ApS
Nordisk Pharma ApS is a Danish company of the type Anpartsselskab based in Vallensbæk, founded in 2021. The company is registered under the industry Fremstilling af medicinske og dentale instrumenter samt udstyr hertil. The management consists of Sayed Edris Sadat and Sanad Emad Hussein Al Bidany. The company is owned by Nordisk Pharma Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 365,248 and a net result of DKK 207,225 compared with DKK 425,521 the year before. Equity in the 2025 report amounted to DKK 1,216,729.